JP2006508127A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006508127A5 JP2006508127A5 JP2004551819A JP2004551819A JP2006508127A5 JP 2006508127 A5 JP2006508127 A5 JP 2006508127A5 JP 2004551819 A JP2004551819 A JP 2004551819A JP 2004551819 A JP2004551819 A JP 2004551819A JP 2006508127 A5 JP2006508127 A5 JP 2006508127A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- beneficial agent
- administration
- polymer
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 48
- 239000003795 chemical substances by application Substances 0.000 claims 31
- 230000009286 beneficial effect Effects 0.000 claims 29
- 229920000642 polymer Polymers 0.000 claims 25
- 238000012384 transportation and delivery Methods 0.000 claims 17
- 238000000034 method Methods 0.000 claims 16
- 239000002904 solvent Substances 0.000 claims 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 7
- 229920000249 biocompatible polymer Polymers 0.000 claims 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims 6
- -1 polyphosphoesters Polymers 0.000 claims 6
- 229920001577 copolymer Polymers 0.000 claims 5
- 239000003607 modifier Substances 0.000 claims 5
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims 4
- 238000009472 formulation Methods 0.000 claims 4
- 230000002459 sustained effect Effects 0.000 claims 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 claims 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical group OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 3
- 239000004310 lactic acid Substances 0.000 claims 3
- 235000014655 lactic acid Nutrition 0.000 claims 3
- 229920000747 poly(lactic acid) Polymers 0.000 claims 3
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 claims 2
- YEJRWHAVMIAJKC-UHFFFAOYSA-N 4-Butyrolactone Chemical compound O=C1CCCO1 YEJRWHAVMIAJKC-UHFFFAOYSA-N 0.000 claims 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims 2
- ZFOZVQLOBQUTQQ-UHFFFAOYSA-N Tributyl citrate Chemical compound CCCCOC(=O)CC(O)(C(=O)OCCCC)CC(=O)OCCCC ZFOZVQLOBQUTQQ-UHFFFAOYSA-N 0.000 claims 2
- UYXTWWCETRIEDR-UHFFFAOYSA-N Tributyrin Chemical compound CCCC(=O)OCC(OC(=O)CCC)COC(=O)CCC UYXTWWCETRIEDR-UHFFFAOYSA-N 0.000 claims 2
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 claims 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical group C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 claims 2
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 claims 2
- 239000003995 emulsifying agent Substances 0.000 claims 2
- JBKVHLHDHHXQEQ-UHFFFAOYSA-N epsilon-caprolactam Chemical compound O=C1CCCCCN1 JBKVHLHDHHXQEQ-UHFFFAOYSA-N 0.000 claims 2
- LZCLXQDLBQLTDK-UHFFFAOYSA-N ethyl 2-hydroxypropanoate Chemical compound CCOC(=O)C(C)O LZCLXQDLBQLTDK-UHFFFAOYSA-N 0.000 claims 2
- MTZQAGJQAFMTAQ-UHFFFAOYSA-N ethyl benzoate Chemical group CCOC(=O)C1=CC=CC=C1 MTZQAGJQAFMTAQ-UHFFFAOYSA-N 0.000 claims 2
- 229920001610 polycaprolactone Polymers 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 claims 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical group CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 claims 2
- 239000001069 triethyl citrate Substances 0.000 claims 2
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 claims 2
- 235000013769 triethyl citrate Nutrition 0.000 claims 2
- PAPBSGBWRJIAAV-UHFFFAOYSA-N ε-Caprolactone Chemical group O=C1CCCCCO1 PAPBSGBWRJIAAV-UHFFFAOYSA-N 0.000 claims 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims 1
- GUSTUIJJPMXTTI-UHFFFAOYSA-N 1-dodecylazepane Chemical compound CCCCCCCCCCCCN1CCCCCC1 GUSTUIJJPMXTTI-UHFFFAOYSA-N 0.000 claims 1
- NZJXADCEESMBPW-UHFFFAOYSA-N 1-methylsulfinyldecane Chemical compound CCCCCCCCCCS(C)=O NZJXADCEESMBPW-UHFFFAOYSA-N 0.000 claims 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims 1
- QZCLKYGREBVARF-UHFFFAOYSA-N Acetyl tributyl citrate Chemical compound CCCCOC(=O)CC(C(=O)OCCCC)(OC(C)=O)CC(=O)OCCCC QZCLKYGREBVARF-UHFFFAOYSA-N 0.000 claims 1
- 229920002101 Chitin Polymers 0.000 claims 1
- 229920001661 Chitosan Polymers 0.000 claims 1
- KMTRUDSVKNLOMY-UHFFFAOYSA-N Ethylene carbonate Chemical compound O=C1OCCO1 KMTRUDSVKNLOMY-UHFFFAOYSA-N 0.000 claims 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims 1
- 239000004348 Glyceryl diacetate Substances 0.000 claims 1
- 239000005642 Oleic acid Substances 0.000 claims 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims 1
- 229920002732 Polyanhydride Polymers 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 229920000954 Polyglycolide Polymers 0.000 claims 1
- 229920001710 Polyorthoester Polymers 0.000 claims 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 claims 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 125000005907 alkyl ester group Chemical group 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims 1
- 235000019445 benzyl alcohol Nutrition 0.000 claims 1
- 229960002903 benzyl benzoate Drugs 0.000 claims 1
- 229920002988 biodegradable polymer Polymers 0.000 claims 1
- 229930188620 butyrolactone Natural products 0.000 claims 1
- YSAVZVORKRDODB-WDSKDSINSA-N diethyl tartrate Chemical compound CCOC(=O)[C@@H](O)[C@H](O)C(=O)OCC YSAVZVORKRDODB-WDSKDSINSA-N 0.000 claims 1
- 229940116333 ethyl lactate Drugs 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- 125000005456 glyceride group Chemical group 0.000 claims 1
- 235000011187 glycerol Nutrition 0.000 claims 1
- 229940074076 glycerol formal Drugs 0.000 claims 1
- 235000019443 glyceryl diacetate Nutrition 0.000 claims 1
- 239000001087 glyceryl triacetate Substances 0.000 claims 1
- 235000013773 glyceryl triacetate Nutrition 0.000 claims 1
- 229920002674 hyaluronan Polymers 0.000 claims 1
- 229960003160 hyaluronic acid Drugs 0.000 claims 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims 1
- 239000001630 malic acid Substances 0.000 claims 1
- 235000011090 malic acid Nutrition 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000002480 mineral oil Substances 0.000 claims 1
- 235000010446 mineral oil Nutrition 0.000 claims 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims 1
- 229920001308 poly(aminoacid) Polymers 0.000 claims 1
- 229920002463 poly(p-dioxanone) polymer Polymers 0.000 claims 1
- 229920002627 poly(phosphazenes) Polymers 0.000 claims 1
- 229920000768 polyamine Polymers 0.000 claims 1
- 229920001083 polybutene Polymers 0.000 claims 1
- 229920001748 polybutylene Polymers 0.000 claims 1
- 229920001707 polybutylene terephthalate Polymers 0.000 claims 1
- 229920005646 polycarboxylate Polymers 0.000 claims 1
- 239000000622 polydioxanone Substances 0.000 claims 1
- 229920000728 polyester Polymers 0.000 claims 1
- 229920006149 polyester-amide block copolymer Polymers 0.000 claims 1
- 229920001855 polyketal Polymers 0.000 claims 1
- 229920006324 polyoxymethylene Polymers 0.000 claims 1
- 229920001282 polysaccharide Polymers 0.000 claims 1
- 239000005017 polysaccharide Substances 0.000 claims 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
- 239000011148 porous material Substances 0.000 claims 1
- RUOJZAUFBMNUDX-UHFFFAOYSA-N propylene carbonate Chemical compound CC1COC(=O)O1 RUOJZAUFBMNUDX-UHFFFAOYSA-N 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 229920002545 silicone oil Polymers 0.000 claims 1
- 150000003890 succinate salts Chemical class 0.000 claims 1
- 238000012385 systemic delivery Methods 0.000 claims 1
- 229920001897 terpolymer Polymers 0.000 claims 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 229960002622 triacetin Drugs 0.000 claims 1
- WEAPVABOECTMGR-UHFFFAOYSA-N triethyl 2-acetyloxypropane-1,2,3-tricarboxylate Chemical compound CCOC(=O)CC(C(=O)OCC)(OC(C)=O)CC(=O)OCC WEAPVABOECTMGR-UHFFFAOYSA-N 0.000 claims 1
- DQWPFSLDHJDLRL-UHFFFAOYSA-N triethyl phosphate Chemical compound CCOP(=O)(OCC)OCC DQWPFSLDHJDLRL-UHFFFAOYSA-N 0.000 claims 1
Claims (48)
- 投与後のあらかじめ定められた持続時間にわたり制御された仕方で対象者へ有益薬剤を持続的送達するための注射可能なデポー組成物であって:
(a)(1)生体分解性で生体適合性のポリマー;および
(2)該ポリマーを可塑化してそれでゲルを形成するのに有効な量の溶剤であって、25℃で7重量%未満またはそれに等しい水混和性を有する溶剤;
を含む粘性ゲル配合物;および
(b)該ゲル中に溶解または分散された有益薬剤;
を含み:
前記持続時間は、投与後約2週間から約12ヵ月までである注射可能デポー組成物。 - 該ポリマーが乳酸およびグリコール酸の共重合体である、請求項1の組成物。
- 該ポリマーがポリラクチドである、請求項1の組成物。
- 該ポリマーがカプロラクトンベースのポリマーである、請求項1の組成物。
- 該ポリマーが乳酸ベースのポリマーである、請求項1の組成物。
- 該ポリマーが約50:50から約100:0のL/G比および約3,000から約120,000までの範囲の分子量をもつ、請求項2の組成物。
- 前記生体分解性で生体適合性のポリマーの約5重量%から約90重量%までを含む、請求項1の組成物。
- 前記生体分解性で生体適合性のポリマーの約25重量%から約80重量%までを含む、請求項7の組成物。
- 前記生体分解性で生体適合性のポリマーの約35重量%から約75重量%までを含む、請求項7の組成物。
- 前記持続時間が投与後3ヵ月に等しいかまたはそれより長い、請求項1の組成物。
- 前記持続時間が投与後約3ヵ月から約6ヵ月までの、請求項1の組成物。
- 前記持続時間が投与後約3ヵ月から約9ヵ月までの、請求項1の組成物。
- 前記持続時間が投与後約6ヵ月から約9ヵ月までの、請求項1の組成物。
- 該粘性ゲルが、ポリラクチド類、ポリグリコリド類、カプラクトンベースの重合体類、ポリ(カプロラクトン)、ポリ無水物類、ポリアミン類、ポリエステルアミド類、ポリオルトエステル類、ポリジオキサノン類、ポリアセタール類、ポリケタール類、ポリカルボン酸塩類、ポリホスホエステル類、ポリエステル類、ポリブチレンテレフタル酸塩、ポリオルトカルボン酸塩類、ポリホスファゼン類、コハク酸塩類、ポリ(リンゴ酸)、ポリ(アミノ酸類)、ポリビニルピロリドン、ポリエチレングリコール、ポリヒドロキシセルロース、多糖類、キチン、キトサン、ヒアルロン酸、および共重合体類、三元共重合体類、およびそれらの混合物類、およびカプラクトンベースの重合体類、ポリカプロラクトン類、およびポリブチレンテレフタル酸塩を含む共重合体類を含む、生分解性およびそれらの共重合体類からなる群から選択されるポリマーを、さらに含む、請求項1の組成物。
- 次のものの少なくとも1つ、細孔形成剤;有益薬剤用の溶解性調整剤;および浸透剤:をさらに含む、請求項1の組成物。
- 該溶剤が、トリアセチン、ジアセチン、トリブチリン、クエン酸トリエチル(トリエチルシトレートに同じ、以下同様)、トリブチルシトレート、アセチルトリエチルシトレート、アセチルトリブチルシトレート、トリエチルグリセリド類、トリエチルホスフェート、ジエチルフタレート、ジエチルタートレート、鉱油、ポリブテン、シリコーン油、グリセリン、エチレングリコール、ポリエチレングリコール、オクタノール、エチルラクテート、プロピレングリコール、プロピレンカーボネート、エチレンカーボネート、ブチロラクトン、エチレンオキシド、プロピレンオキシド、N・メチル・2・ピロリドン、2・ピロリドン、グリセロールホルマル、メチルアセテート、エチルアセテート、メチルエチルケトン、ジメチルホルムアミド、ジメチルスルフォキシド、テトラヒドロフラン、カプロラクタム、デシルメチルスルフォキシド、オレイン酸、および1・ドデシルアザシクロ・ヘプタン・2・オン、およびそれらの混合物、からなる群から選択される成分溶剤を含む、請求項1の組成物。
- 該溶剤が、芳香族アルコール、アリール酸類の低級アルキルおよびアラルキルエステル類;アリール、アラルキルおよび低級アルキルケトン類;およびクエン酸の低級アルキルエステル類から選択される、請求項1の組成物。
- 該溶剤がベンジルアルコールである、請求項1の組成物。
- 該溶剤がベンジルベンゾエートである、請求項1の組成物。
- 該溶剤がエチルベンゾエートである、請求項1の組成物。
- 該組成物が25℃で7重量%より大きい水との混和性をもつ溶剤を含まない、請求項1の組成物。
- 前記送達が全身的送達である、請求項1の組成物。
- 前記送達が局所的送達である、請求項1の組成物。
- 前記送達が或る期間後に反復される、請求項1の組成物。
- 前記送達が複数の部位で提供される、請求項1の組成物。
- 該有益薬剤が投与後約2週間から約12ヵ月までの持続時間にわたって制御された仕方で全身的に送達される、請求項22の注射可能デポー組成物。
- 該有益薬剤が投与後約2週間から約12ヵ月までの持続時間にわたって制御された仕方で局所的に送達される、請求項23の注射可能デポー組成物。
- 投与後のあらかじめ定められた持続時間にわたって、制御された仕方で、対象者に有益薬剤を投与する方法であって:
(i)対象者へ、
(a)(1)生体分解性で生体適合性のポリマー;および
(2)該ポリマーを可塑化してそれでゲルを形成するのに有効な量の、25℃で7重量%未満またはそれに等しい水への混和性を有する溶剤;
を含む粘性ゲル配合物;
を投与すること:
(b)該ゲル中に溶解または分散された有益薬剤;および
(ii)投与後約2週間から約12ヵ月までの持続時間にわたって、対象者に該有益薬剤を送達すること:
を含む前記方法。 - 制御された仕方で対象者に有益薬剤を全身的に送達することをさらに含む、請求項28の方法。
- 或る期間後に送達工程(ii)を反復することをさらに含む、請求項28の方法。
- 或る期間後に送達工程(ii)を反復することをさらに含む、請求項29の方法。
- 制御された仕方で対象者に有益薬剤を局所的に送達することをさらに含む、請求項28の方法。
- 或る期間後に送達工程(ii)を反復することをさらに含む、請求項32の方法。
- 複数の部位で送達工程(ii)を行うことをさらに含む、請求項32の方法。
- 投与後のあらかじめ定められた持続時間にわたって、制御された仕方で、対象者に有益薬剤の持続的送達のための投与のためのキットであって:
(a)生体分解性で生体適合性のポリマー;
(b)該ポリマーを可塑化しそれでゲルを形成するのに有効な量の、25℃で7重量%未満またはそれに等しい水との混和性をもつ溶剤;
(c)該ゲル中に溶解または分散された有益薬剤;および、場合により次のものの1つ以上:
(d)乳化剤;
(e)細孔形成剤;
(f)場合により有益薬剤に結合する該有益薬剤用の溶解性調整剤;および
(g)浸透剤;
を含み、
ここで、少なくとも、場合により該溶解性調整剤に結合する該有益薬剤は、対象者への有益薬剤の投与のときまで、該溶剤から分離されて維持される、前記キット。 - 投与後のあらかじめ定められた持続時間にわたって、制御された仕方で、対象者に有益薬剤を持続的に送達するための、注射可能デポー組成物であって:
(a)(1)ポリマー類の生体分解性で生体適合性の混合物;および
(2)該ポリマーを可塑化しそれでゲルを形成するのに有効な量で、25℃で7重量%未満またはそれに等しい水との混和性をもつ溶剤;
を含む粘性ゲル配合物;および
(b)該ゲル中に溶解または分散された有益薬剤;
を含み:
ここで、前記持続時間が投与後約2週間から約12ヵ月までである、前記注射可能デポー組成物。 - 前記ポリマー類の混合物が乳酸およびグリコール酸の共重合体を含む、請求項36の組成物。
- 前記ポリマー類の混合物がポリラクチドを含む、請求項36の組成物。
- 前記ポリマー類の混合物がカプロラクトンベースのポリマーを含む、請求項36の組成物。
- 前記ポリマー類の混合物が約50:50から約100:0のL/G比および約3,000から約120,000までの範囲の分子量をもつポリマーを含む、請求項36の組成物
- 投与後のあらかじめ定められた持続時間にわたって、制御された仕方で、対象者に有益薬剤を投与する方法であって:
(i)対象者へ、
(a)(1)ポリマー類の生体分解性で生体適合性の混合物;および
(2)該ポリマーを可塑化しそれでゲルを形成するのに有効な量の、25℃で7重量%未満またはそれに等しい水との混和性をもつ溶剤;
を含む粘性ゲル配合物;および
(b)該ゲル中に溶解または分散された有益薬剤;
を投与すること:および
(ii)投与後約2週間から約12ヵ月までの持続時間にわたって、対象者に該有益薬剤を送達すること:
を含む前記方法。 - 制御された仕方で対象者に有益薬剤を全身的に送達することをさらに含む、請求項41の方法。
- 或る期間後に送達工程(ii)を反復することをさらに含む、請求項41の方法。
- 或る期間後に送達工程(ii)を反復することをさらに含む、請求項42の方法。
- 制御された仕方で対象者に有益薬剤を局所的に送達することをさらに含む、請求項41の方法。
- 或る期間後に送達工程(ii)を反復することをさらに含む、請求項45の方法。
- 複数の部位で送達工程(ii)を行うことをさらに含む、請求項45の方法。
- 投与後のあらかじめ定められた持続時間にわたって、制御された仕方で、対象者に有益薬剤の持続的送達のための投与のためのキットであって:
(a)ポリマー類の生体分解性で生体適合性の混合物;
(b)該ポリマー類を可塑化しそれでゲルを形成するのに有効な量の、25℃で7重量%未満またはそれに等しい水との混和性をもつ溶剤;
(c)該ゲル中に溶解または分散された有益薬剤;および、場合により次のものの1つ以上:
(d)乳化剤;
(e)細孔形成剤;
(f)場合により有益薬剤と結合する該有益薬剤用の溶解性調整剤;および
(g)浸透剤;
を含み、
ここで、場合により該溶解性調整剤に結合する少なくとも該有益薬剤は、対象者への有益薬剤の投与のときまで、該溶剤から分離されて維持される、前記キット。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42442802P | 2002-11-06 | 2002-11-06 | |
| PCT/US2003/035416 WO2004043432A2 (en) | 2002-11-06 | 2003-11-04 | Controlled release depot formulations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006508127A JP2006508127A (ja) | 2006-03-09 |
| JP2006508127A5 true JP2006508127A5 (ja) | 2006-12-28 |
Family
ID=32312806
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004551819A Pending JP2006508127A (ja) | 2002-11-06 | 2003-11-04 | 制御された放出性デポー剤配合物 |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US7368126B2 (ja) |
| EP (1) | EP1581181B1 (ja) |
| JP (1) | JP2006508127A (ja) |
| KR (1) | KR20050088288A (ja) |
| CN (1) | CN1713890A (ja) |
| AR (1) | AR041913A1 (ja) |
| AT (1) | ATE418323T1 (ja) |
| AU (1) | AU2003295409B2 (ja) |
| BR (1) | BR0315304A (ja) |
| CA (1) | CA2504608C (ja) |
| CL (1) | CL2003002277A1 (ja) |
| DE (1) | DE60325511D1 (ja) |
| EC (2) | ECSP055838A (ja) |
| MA (1) | MA27523A1 (ja) |
| MX (1) | MXPA05004927A (ja) |
| MY (1) | MY140155A (ja) |
| NO (1) | NO20052635L (ja) |
| NZ (1) | NZ539810A (ja) |
| PE (1) | PE20040675A1 (ja) |
| PL (1) | PL377333A1 (ja) |
| RU (1) | RU2355385C2 (ja) |
| TW (1) | TW200503774A (ja) |
| UY (1) | UY28067A1 (ja) |
| WO (1) | WO2004043432A2 (ja) |
| ZA (1) | ZA200504529B (ja) |
Families Citing this family (145)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5869079A (en) * | 1995-06-02 | 1999-02-09 | Oculex Pharmaceuticals, Inc. | Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents |
| US20060280774A1 (en) * | 1995-06-02 | 2006-12-14 | Allergan, Inc. | Compositions and methods for treating glaucoma |
| WO2001036000A1 (en) * | 1999-11-15 | 2001-05-25 | Bio Syntech Canada, Inc. | Temperature-controlled and ph-dependant self-gelling biopolymeric aqueous solution |
| US20030158302A1 (en) * | 1999-12-09 | 2003-08-21 | Cyric Chaput | Mineral-polymer hybrid composition |
| DE60004710T2 (de) * | 1999-12-09 | 2004-07-08 | Biosyntech Canada Inc., Laval | Mineral-polymer hybrid-zusammensetzung |
| US20050042194A1 (en) | 2000-05-11 | 2005-02-24 | A.P. Pharma, Inc. | Semi-solid delivery vehicle and pharmaceutical compositions |
| ATE320277T1 (de) * | 2000-06-29 | 2006-04-15 | Biosyntech Canada Inc | Zusammensetzung und verfahren zur reparatur und regenerierung von knorpel und anderen geweben |
| US6726918B1 (en) | 2000-07-05 | 2004-04-27 | Oculex Pharmaceuticals, Inc. | Methods for treating inflammation-mediated conditions of the eye |
| US20040018228A1 (en) * | 2000-11-06 | 2004-01-29 | Afmedica, Inc. | Compositions and methods for reducing scar tissue formation |
| AU2002221370A1 (en) * | 2000-11-15 | 2002-05-27 | Bio Syntech Canada Inc | Method for restoring a damaged or degenerated intervertebral disc |
| EP1339438B1 (en) * | 2000-11-29 | 2005-10-19 | Allergan Inc. | Preventing transplant rejection in the eye |
| MXPA04004665A (es) * | 2001-11-14 | 2004-09-10 | Alza Corp | Composiciones de deposito inyectable y uso de los mismos. |
| US20070196415A1 (en) * | 2002-11-14 | 2007-08-23 | Guohua Chen | Depot compositions with multiple drug release rate controls and uses thereof |
| US20040001889A1 (en) | 2002-06-25 | 2004-01-01 | Guohua Chen | Short duration depot formulations |
| BR0313539A (pt) | 2002-07-31 | 2005-06-21 | Alza Corp | Composições depósito de polìmero multimodais injetáveis e seus usos |
| WO2004012703A1 (en) * | 2002-07-31 | 2004-02-12 | Alza Corporation | Injectable depot compositions and uses thereof |
| US7731947B2 (en) | 2003-11-17 | 2010-06-08 | Intarcia Therapeutics, Inc. | Composition and dosage form comprising an interferon particle formulation and suspending vehicle |
| US20050048099A1 (en) * | 2003-01-09 | 2005-03-03 | Allergan, Inc. | Ocular implant made by a double extrusion process |
| CL2004000697A1 (es) * | 2003-03-31 | 2005-05-20 | Alza Corp | Dispositivo de administracion osmotica que comprende: un reservorio, una composicion osmotica, la formulacion de la droga, y una membrana precargada que comprende un material semipermeable y un material liquido de relleno seleccionado de un polietile |
| TW200507893A (en) * | 2003-03-31 | 2005-03-01 | Alza Corp | Osmotic pump with means for dissipating internal pressure |
| NZ542867A (en) * | 2003-03-31 | 2009-02-28 | Durect Corp | Non-aqueous single phase vehicles and formulations utilizing such vehicles involving a polymer |
| AU2004245022A1 (en) * | 2003-05-30 | 2004-12-16 | Alza Corporation | Implantable elastomeric depot compositions, uses thereof and method of manufacturing |
| US20070184084A1 (en) * | 2003-05-30 | 2007-08-09 | Guohua Chen | Implantable elastomeric caprolactone depot compositions and uses thereof |
| US20050106214A1 (en) * | 2003-11-14 | 2005-05-19 | Guohua Chen | Excipients in drug delivery vehicles |
| US8425929B2 (en) | 2004-04-30 | 2013-04-23 | Allergan, Inc. | Sustained release intraocular implants and methods for preventing retinal dysfunction |
| US20050244458A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Sustained release intraocular implants and methods for treating ocular neuropathies |
| US8722097B2 (en) | 2004-04-30 | 2014-05-13 | Allergan, Inc. | Oil-in-water method for making polymeric implants containing a hypotensive lipid |
| US8685435B2 (en) * | 2004-04-30 | 2014-04-01 | Allergan, Inc. | Extended release biodegradable ocular implants |
| US20050244463A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Sustained release intraocular implants and methods for treating ocular vasculopathies |
| US7799336B2 (en) | 2004-04-30 | 2010-09-21 | Allergan, Inc. | Hypotensive lipid-containing biodegradable intraocular implants and related methods |
| US8673341B2 (en) | 2004-04-30 | 2014-03-18 | Allergan, Inc. | Intraocular pressure reduction with intracameral bimatoprost implants |
| US9498457B2 (en) | 2004-04-30 | 2016-11-22 | Allergan, Inc. | Hypotensive prostamide-containing biodegradable intraocular implants and related implants |
| US8119154B2 (en) * | 2004-04-30 | 2012-02-21 | Allergan, Inc. | Sustained release intraocular implants and related methods |
| US20050244469A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Extended therapeutic effect ocular implant treatments |
| US7993634B2 (en) | 2004-04-30 | 2011-08-09 | Allergan, Inc. | Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods |
| WO2005107708A1 (en) | 2004-04-30 | 2005-11-17 | Allergan, Inc. | Biodegradable intravitreal tyrosine kinase inhibitors implants |
| US8529927B2 (en) * | 2004-04-30 | 2013-09-10 | Allergan, Inc. | Alpha-2 agonist polymeric drug delivery systems |
| US20050266087A1 (en) * | 2004-05-25 | 2005-12-01 | Gunjan Junnarkar | Formulations having increased stability during transition from hydrophobic vehicle to hydrophilic medium |
| WO2006078320A2 (en) | 2004-08-04 | 2006-07-27 | Brookwood Pharmaceuticals, Inc. | Methods for manufacturing delivery devices and devices thereof |
| US9993558B2 (en) | 2004-10-01 | 2018-06-12 | Ramscor, Inc. | Sustained release eye drop formulations |
| US20080038316A1 (en) * | 2004-10-01 | 2008-02-14 | Wong Vernon G | Conveniently implantable sustained release drug compositions |
| US8541413B2 (en) * | 2004-10-01 | 2013-09-24 | Ramscor, Inc. | Sustained release eye drop formulations |
| MX366832B (es) * | 2004-10-01 | 2019-07-24 | Ramscor Inc | Composiciones de farmaco de liberacion sostenida convenientemente implantables. |
| TWI369218B (en) * | 2004-12-14 | 2012-08-01 | Novartis Ag | In situ forming implant for animals |
| EP1838285A2 (en) * | 2004-12-15 | 2007-10-03 | QLT USA, Inc. | Sustained delivery formulations of octreotide compounds |
| US20060141040A1 (en) * | 2004-12-23 | 2006-06-29 | Guohua Chen | Injectable non-aqueous suspension |
| WO2006083761A2 (en) | 2005-02-03 | 2006-08-10 | Alza Corporation | Solvent/polymer solutions as suspension vehicles |
| US11246913B2 (en) | 2005-02-03 | 2022-02-15 | Intarcia Therapeutics, Inc. | Suspension formulation comprising an insulinotropic peptide |
| EP1871348A4 (en) * | 2005-03-01 | 2012-08-01 | Sun Pharma Advanced Res Co Ltd | PHARMACEUTICAL COMPOSITIONS WITH DELAYED RELEASE |
| BRPI0613731A2 (pt) * | 2005-07-12 | 2011-02-01 | Renovo Ltd | composição farmacêutica, recipiente enchido previamente, bem como uso de um açúcar para aprimorar a recuperação e/ou aumentar a atividade biológica de um membro da superfamìlia tgf-beta |
| US20070027105A1 (en) | 2005-07-26 | 2007-02-01 | Alza Corporation | Peroxide removal from drug delivery vehicle |
| US8852638B2 (en) * | 2005-09-30 | 2014-10-07 | Durect Corporation | Sustained release small molecule drug formulation |
| EP1948810A4 (en) * | 2005-11-04 | 2010-06-30 | Biosyntech Canada Inc | COMPOSITION AND METHOD USING CHITOSAN FOR THE EFFICIENT ADMINISTRATION OF NUCLEIC ACIDS TO CELLS |
| US20090048667A1 (en) * | 2005-11-16 | 2009-02-19 | Tokai University Educational System | Controlled Drug-Release Composition and Drug-Releasable Medical Device |
| AR058591A1 (es) * | 2005-12-22 | 2008-02-13 | Novartis Ag | Formulacion de liberacion sostenida que comprende octreotida y dos o mas polimeros de polilactido-coglicolido |
| US8236904B2 (en) | 2005-12-28 | 2012-08-07 | Ethicon, Inc. | Bioabsorbable polymer compositions exhibiting enhanced crystallization and hydrolysis rates |
| US20070149640A1 (en) * | 2005-12-28 | 2007-06-28 | Sasa Andjelic | Bioabsorbable polymer compositions exhibiting enhanced crystallization and hydrolysis rates |
| US20070178138A1 (en) * | 2006-02-01 | 2007-08-02 | Allergan, Inc. | Biodegradable non-opthalmic implants and related methods |
| JP5143131B2 (ja) | 2006-05-30 | 2013-02-13 | インターシア セラピューティクス,インコーポレイティド | 浸透圧送出システムの二片構成内部チャネル型の流れモジュレータ |
| US8802128B2 (en) * | 2006-06-23 | 2014-08-12 | Allergan, Inc. | Steroid-containing sustained release intraocular implants and related methods |
| US20070298073A1 (en) * | 2006-06-23 | 2007-12-27 | Allergan, Inc. | Steroid-containing sustained release intraocular implants and related methods |
| AU2007284759B2 (en) | 2006-08-09 | 2010-10-28 | Intarcia Therapeutics, Inc. | Osmotic delivery systems and piston assemblies |
| US8969415B2 (en) * | 2006-12-01 | 2015-03-03 | Allergan, Inc. | Intraocular drug delivery systems |
| US8846073B2 (en) | 2006-12-19 | 2014-09-30 | Allergan, Inc. | Low temperature processes for making cyclic lipid implants for intraocular use |
| CN101715340A (zh) | 2007-04-23 | 2010-05-26 | 精达制药公司 | 促胰岛素释放肽的混悬制剂及其应用 |
| HUE030789T2 (en) | 2007-05-18 | 2017-06-28 | Durect Corp | Improved depot formulation |
| WO2008153611A2 (en) | 2007-05-25 | 2008-12-18 | Qlt Usa, Inc. | Sustained delivery formulations of risperidone compounds |
| WO2008149364A2 (en) * | 2007-06-07 | 2008-12-11 | Sarah Brenner | Methods for diagnosing hypersensitivity reactions |
| US7923021B2 (en) * | 2007-07-24 | 2011-04-12 | University Of Memphis Research Foundation | Local delivery method and composition |
| RU2343908C1 (ru) * | 2007-09-05 | 2009-01-20 | Руслан Дмитриевич Илюк | Средство для профилактики и лечения алкоголизма и способ его применения |
| US8470360B2 (en) * | 2008-04-18 | 2013-06-25 | Warsaw Orthopedic, Inc. | Drug depots having different release profiles for reducing, preventing or treating pain and inflammation |
| CA2705520C (en) * | 2007-11-13 | 2016-06-28 | Surmodics Pharmaceuticals, Inc. | Viscous terpolymers as drug delivery platform |
| US8728528B2 (en) | 2007-12-20 | 2014-05-20 | Evonik Corporation | Process for preparing microparticles having a low residual solvent volume |
| AU2013201877B2 (en) * | 2008-01-30 | 2015-01-29 | Novartis Ag | Sustained release formulation comprising octreotide and three linear polylactide-co-glycolide polymers |
| CN101917969A (zh) * | 2008-01-30 | 2010-12-15 | 诺瓦提斯公司 | 包含奥曲肽和三种线形聚丙交酯-共-乙交酯聚合物的缓释制剂 |
| US8343140B2 (en) | 2008-02-13 | 2013-01-01 | Intarcia Therapeutics, Inc. | Devices, formulations, and methods for delivery of multiple beneficial agents |
| US8846068B2 (en) * | 2008-04-18 | 2014-09-30 | Warsaw Orthopedic, Inc. | Methods and compositions for treating post-operative pain comprising a local anesthetic |
| US8956641B2 (en) * | 2008-04-18 | 2015-02-17 | Warsaw Orthopedic, Inc. | Alpha adrenergic receptor agonists for treatment of inflammatory diseases |
| US8889173B2 (en) * | 2008-04-18 | 2014-11-18 | Warsaw Orthopedic, Inc. | Alpha adrenergic receptor agonists for treatment of pain and/or inflammation |
| US8524267B2 (en) * | 2008-04-18 | 2013-09-03 | Warsaw Orthopedic, Inc. | Dexamethasone formulations in a biodegradable material |
| US7993666B2 (en) * | 2008-04-18 | 2011-08-09 | Warsaw Orthopedic, Inc. | Methods and compositions for treating pain comprising a statin |
| US8883768B2 (en) * | 2008-04-18 | 2014-11-11 | Warsaw Orthopedic, Inc. | Fluocinolone implants to protect against undesirable bone and cartilage destruction |
| US9072727B2 (en) * | 2008-04-18 | 2015-07-07 | Warsaw Orthopedic, Inc. | Alpha adrenergic receptor agonists for treatment of degenerative disc disease |
| US20090263456A1 (en) * | 2008-04-18 | 2009-10-22 | Warsaw Orthopedic, Inc. | Methods and Compositions for Reducing Preventing and Treating Adhesives |
| US8846770B2 (en) * | 2008-06-18 | 2014-09-30 | Otonomy, Inc. | Controlled release aural pressure modulator compositions and methods for the treatment of OTIC disorders |
| KR101760953B1 (ko) * | 2008-09-04 | 2017-07-24 | 아밀린 파마슈티칼스, 엘엘씨. | 비-수성 담체를 이용한 서방성 제형물 |
| US9623222B2 (en) * | 2008-10-30 | 2017-04-18 | Warsaw Orthopedic, Inc. | Drug depot with anchor |
| US9095506B2 (en) | 2008-11-17 | 2015-08-04 | Allergan, Inc. | Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof |
| US20100151033A1 (en) * | 2008-12-15 | 2010-06-17 | Novartis Ag | Octreotide depot formulation with constantly high exposure levels |
| US20100158978A1 (en) * | 2008-12-23 | 2010-06-24 | Peter Markland | Bioactive spray coating compositions and methods of making and uses thereof |
| US8951546B2 (en) | 2008-12-23 | 2015-02-10 | Surmodics Pharmaceuticals, Inc. | Flexible implantable composites and implants comprising same |
| US20100168807A1 (en) * | 2008-12-23 | 2010-07-01 | Burton Kevin W | Bioactive terpolymer compositions and methods of making and using same |
| US9415197B2 (en) | 2008-12-23 | 2016-08-16 | Surmodics, Inc. | Implantable suction cup composites and implants comprising same |
| US8974808B2 (en) * | 2008-12-23 | 2015-03-10 | Surmodics, Inc. | Elastic implantable composites and implants comprising same |
| US20100228097A1 (en) * | 2009-03-04 | 2010-09-09 | Warsaw Orthopedic, Inc. | Methods and compositions to diagnose pain |
| US20100247606A1 (en) * | 2009-03-25 | 2010-09-30 | Allergan, Inc. | Intraocular sustained release drug delivery systems and methods for treating ocular conditions |
| EP2475396A4 (en) * | 2009-09-10 | 2013-10-16 | Univ Pittsburgh | MANIPULATED MICROPARTICLES FOR THE RELEASE OF MACROMOLECULES |
| KR102093612B1 (ko) | 2009-09-28 | 2020-03-26 | 인타르시아 세라퓨틱스 인코포레이티드 | 실질 항정상태 약물 전달의 신속 확립 및/또는 종결 |
| US20110097380A1 (en) * | 2009-10-28 | 2011-04-28 | Warsaw Orthopedic, Inc. | Clonidine formulations having antimicrobial properties |
| RU2567792C2 (ru) | 2009-11-09 | 2015-11-10 | Аллерган, Инк. | Композиции и способы стимулирования роста волос |
| US9993441B2 (en) | 2009-12-30 | 2018-06-12 | Surmodics, Inc. | Controlled release matrix barrier structure for subcutaneous medical devices |
| EP3085358B1 (en) | 2010-01-22 | 2017-11-01 | Allergan, Inc. | Intracameral sustained release therapeutic agent implants |
| WO2011133370A1 (en) * | 2010-04-23 | 2011-10-27 | Medtronic, Inc. | Shelf stable pharmaceutical depot |
| US9272044B2 (en) | 2010-06-08 | 2016-03-01 | Indivior Uk Limited | Injectable flowable composition buprenorphine |
| GB2513267B (en) | 2010-06-08 | 2015-03-18 | Rb Pharmaceuticals Ltd | Injectable flowable composition comprising buprenorphine |
| GB2481017B (en) | 2010-06-08 | 2015-01-07 | Rb Pharmaceuticals Ltd | Microparticle buprenorphine suspension |
| WO2012030819A1 (en) | 2010-08-30 | 2012-03-08 | Surmodics Pharmaceuticals, Inc. | Terpolymers as pressure-sensitive adhesives |
| CA2810842C (en) * | 2010-09-09 | 2018-06-26 | Micell Technologies, Inc. | Macrolide dosage forms |
| US20120208755A1 (en) | 2011-02-16 | 2012-08-16 | Intarcia Therapeutics, Inc. | Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers |
| WO2012125914A1 (en) * | 2011-03-16 | 2012-09-20 | University Of Delaware | Injectable delivery system for heparan sulfate binding growth factors |
| CN102133180B (zh) * | 2011-03-18 | 2016-03-09 | 黄芳 | 一种甾体5α-还原酶抑制剂长效注射制剂及其制备方法 |
| US9005634B2 (en) | 2011-04-13 | 2015-04-14 | Medtronic, Inc. | Shelf stable pharmaceutical depot |
| ES2607497T3 (es) * | 2011-04-25 | 2017-03-31 | Shandong Luye Pharmaceutical Co., Ltd. | Composición de risperidona de microesferas de liberación controlada |
| US8951996B2 (en) * | 2011-07-28 | 2015-02-10 | Lipocine Inc. | 17-hydroxyprogesterone ester-containing oral compositions and related methods |
| WO2013088255A1 (en) * | 2011-12-15 | 2013-06-20 | Alkermes Pharma Ireland Limited | Prodrugs of secondary amine compounds |
| WO2013162270A1 (ko) * | 2012-04-24 | 2013-10-31 | 서울대학교산학협력단 | 약물의 제어 방출이 가능한 유방 보형물 및 이의 제조방법 |
| US8822423B2 (en) * | 2012-05-17 | 2014-09-02 | Janssen Biotech, Inc. | Affinity peptides toward infliximab |
| KR20200065106A (ko) | 2012-09-27 | 2020-06-08 | 알레간 인코포레이티드 | 단백질의 지속된 방출을 위한 생물분해성 약물 전달 시스템 |
| CA2901280A1 (en) | 2013-02-15 | 2014-08-21 | Allergan, Inc. | Sustained drug delivery implant |
| US20140308352A1 (en) | 2013-03-11 | 2014-10-16 | Zogenix Inc. | Compositions and methods involving polymer, solvent, and high viscosity liquid carrier material |
| AU2014249008B2 (en) | 2013-03-11 | 2018-12-06 | Durect Corporation | Injectable controlled release composition comprising high viscosity liquid carrier |
| AU2014228313B2 (en) | 2013-03-15 | 2019-01-17 | Heron Therapeutics, Inc. | Compositions of a polyorthoester and an aprotic solvent |
| SG11201603383VA (en) | 2013-10-31 | 2016-05-30 | Allergan Inc | Prostamide-containing intraocular implants and methods of use thereof |
| WO2015088990A1 (en) | 2013-12-09 | 2015-06-18 | Durect Corporation | Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same |
| WO2015101625A1 (en) * | 2013-12-31 | 2015-07-09 | Pb&B Sa | Controlled release fatty acid compositions for use in body reconstruction and body-shaping |
| GB201404139D0 (en) | 2014-03-10 | 2014-04-23 | Rb Pharmaceuticals Ltd | Sustained release buprenorphine solution formulations |
| US9889085B1 (en) | 2014-09-30 | 2018-02-13 | Intarcia Therapeutics, Inc. | Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c |
| CA3015557C (en) | 2014-11-07 | 2019-07-16 | Indivior Uk Limited | The use of sustained-release buprenorphine formulations for the treatment of pain or opioid use disorders |
| AU2016270984B2 (en) | 2015-06-03 | 2021-02-25 | Intarcia Therapeutics, Inc. | Implant placement and removal systems |
| WO2017015675A1 (en) | 2015-07-23 | 2017-01-26 | Envisia Therapeutics, Inc. | Glaucoma treatment via intracameral ocular implants |
| RU2760007C2 (ru) | 2016-05-16 | 2021-11-22 | Интарсия Терапьютикс, Инк. | Полипептиды, селективные к рецепторам глюкагона, и способы их применения |
| USD860451S1 (en) | 2016-06-02 | 2019-09-17 | Intarcia Therapeutics, Inc. | Implant removal tool |
| USD840030S1 (en) | 2016-06-02 | 2019-02-05 | Intarcia Therapeutics, Inc. | Implant placement guide |
| US10682340B2 (en) | 2016-06-30 | 2020-06-16 | Durect Corporation | Depot formulations |
| KR20190025635A (ko) | 2016-06-30 | 2019-03-11 | 듀렉트 코퍼레이션 | 데포 제형 |
| CA3049034A1 (en) | 2017-01-03 | 2018-07-12 | Intarcia Therapeutics, Inc. | Methods comprising continuous administration of a glp-1 receptor agonist and co-adminstration of a drug |
| JP7254719B2 (ja) | 2017-06-13 | 2023-04-10 | ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア | 薬物送達用のポリマーペースト組成物 |
| US10646484B2 (en) | 2017-06-16 | 2020-05-12 | Indivior Uk Limited | Methods to treat opioid use disorder |
| CN119185557A (zh) | 2018-04-06 | 2024-12-27 | 阿玛治疗公司 | 用于控释治疗剂的组合物 |
| CN109898236B (zh) * | 2019-03-15 | 2021-12-14 | 深圳市光远生物材料有限责任公司 | 一种载药纳米纤维膜及其制备方法和应用 |
| WO2021146215A1 (en) | 2020-01-13 | 2021-07-22 | Durect Corporation | Sustained release drug delivery systems with reduced impurities and related methods |
| CN111548482B (zh) * | 2020-04-02 | 2022-09-13 | 复旦大学 | 一氧化氮供体修饰的共聚物、包含其的缓释制剂及其制备方法与应用 |
| JP2024503402A (ja) | 2021-01-12 | 2024-01-25 | デュレクト コーポレーション | 徐放性薬物送達システム及び関連の方法 |
| WO2023278695A1 (en) * | 2021-06-30 | 2023-01-05 | The University Of North Carolina At Chapel Hill | Injectable, biodegradable and removable polymer based drug suspension for ultra-long-acting drug delivery |
| CN116270491A (zh) * | 2023-03-30 | 2023-06-23 | 北京博恩特药业有限公司 | 一种醋酸亮丙瑞林缓释微球及其制备方法 |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3797492A (en) * | 1972-12-27 | 1974-03-19 | Alza Corp | Device for dispensing product with directional guidance member |
| US3887790A (en) * | 1974-10-07 | 1975-06-03 | Vernon H Ferguson | Wrap-around electric resistance heater |
| US3987790A (en) | 1975-10-01 | 1976-10-26 | Alza Corporation | Osmotically driven fluid dispenser |
| US4008719A (en) * | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| JPS5933320B2 (ja) * | 1981-04-03 | 1984-08-15 | 株式会社東芝 | 光学的情報記録媒体 |
| US4443340A (en) * | 1981-10-09 | 1984-04-17 | Betz Laboratories, Inc. | Control of iron induced fouling in water systems |
| US4985404A (en) * | 1984-10-04 | 1991-01-15 | Monsanto Company | Prolonged release of biologically active polypeptides |
| US4865845A (en) * | 1986-03-21 | 1989-09-12 | Alza Corporation | Release rate adjustment of osmotic or diffusional delivery devices |
| US4853218A (en) * | 1987-02-24 | 1989-08-01 | Schering Corporation | Zinc-protamine-alpha interferon complex |
| US4938763B1 (en) * | 1988-10-03 | 1995-07-04 | Atrix Lab Inc | Biodegradable in-situ forming implants and method of producing the same |
| US5085866A (en) * | 1988-12-02 | 1992-02-04 | Southern Research Institute | Method of producing zero-order controlled-released devices |
| US5057318A (en) * | 1988-12-13 | 1991-10-15 | Alza Corporation | Delivery system for beneficial agent over a broad range of rates |
| US5059423A (en) * | 1988-12-13 | 1991-10-22 | Alza Corporation | Delivery system comprising biocompatible beneficial agent formulation |
| US5324519A (en) * | 1989-07-24 | 1994-06-28 | Atrix Laboratories, Inc. | Biodegradable polymer composition |
| US5112614A (en) * | 1989-09-14 | 1992-05-12 | Alza Corporation | Implantable delivery dispenser |
| US5234693A (en) * | 1990-07-11 | 1993-08-10 | Alza Corporation | Delivery device with a protective sleeve |
| US5234692A (en) * | 1990-07-11 | 1993-08-10 | Alza Corporation | Delivery device with a protective sleeve |
| US5151093A (en) * | 1990-10-29 | 1992-09-29 | Alza Corporation | Osmotically driven syringe with programmable agent delivery |
| US5620700A (en) * | 1990-10-30 | 1997-04-15 | Alza Corporation | Injectable drug delivery system and method |
| GB9027422D0 (en) * | 1990-12-18 | 1991-02-06 | Scras | Osmotically driven infusion device |
| US5137727A (en) * | 1991-06-12 | 1992-08-11 | Alza Corporation | Delivery device providing beneficial agent stability |
| US5288214A (en) * | 1991-09-30 | 1994-02-22 | Toshio Fukuda | Micropump |
| ES2139646T3 (es) * | 1991-12-19 | 2000-02-16 | Mitsui Chemicals Inc | Acido polihidroxido carboxilico y su procedimiento de obtencion. |
| US5456679A (en) * | 1992-02-18 | 1995-10-10 | Alza Corporation | Delivery devices with pulsatile effect |
| US5209746A (en) * | 1992-02-18 | 1993-05-11 | Alza Corporation | Osmotically driven delivery devices with pulsatile effect |
| US5308348A (en) * | 1992-02-18 | 1994-05-03 | Alza Corporation | Delivery devices with pulsatile effect |
| US5656297A (en) * | 1992-03-12 | 1997-08-12 | Alkermes Controlled Therapeutics, Incorporated | Modulated release from biocompatible polymers |
| GB9211268D0 (en) | 1992-05-28 | 1992-07-15 | Ici Plc | Salts of basic peptides with carboxyterminated polyesters |
| US5242910A (en) * | 1992-10-13 | 1993-09-07 | The Procter & Gamble Company | Sustained release compositions for treating periodontal disease |
| DE69329295T2 (de) * | 1992-12-02 | 2001-03-15 | Alkermes Controlled Therapeutics, Inc. | Wachstumhormon enthaltende mikrosphaeren mit kontrollierter freisetzung |
| US5468253A (en) * | 1993-01-21 | 1995-11-21 | Ethicon, Inc. | Elastomeric medical device |
| CA2474701C (en) | 1993-11-19 | 2009-01-27 | Alkermes Controlled Therapeutics Inc. Ii | Preparation of biodegradeable microparticles containing a biologically active agent |
| US5556905A (en) * | 1994-03-30 | 1996-09-17 | Reilly Industries, Inc. | Physically-modified degradable thermoplastic compositions |
| DE69524398T2 (de) * | 1994-04-08 | 2002-07-18 | Atrix Laboratories, Inc. | Flüssige mittel zur wirkstoffabgabe |
| US5626862A (en) * | 1994-08-02 | 1997-05-06 | Massachusetts Institute Of Technology | Controlled local delivery of chemotherapeutic agents for treating solid tumors |
| UA10911C2 (uk) * | 1994-08-10 | 1996-12-25 | Мале Впроваджувальне Підприємство "Іhтерфалл" | Біосумісhий гідрогель |
| US5639851A (en) * | 1995-10-02 | 1997-06-17 | Ethicon, Inc. | High strength, melt processable, lactide-rich, poly(lactide-CO-P-dioxanone) copolymers |
| US6113624A (en) * | 1995-10-02 | 2000-09-05 | Ethicon, Inc. | Absorbable elastomeric polymer |
| WO1998027962A2 (en) * | 1996-12-20 | 1998-07-02 | Alza Corporation | Injectable depot gel composition and method of preparing the composition |
| US6193991B1 (en) * | 1997-10-29 | 2001-02-27 | Atul J. Shukla | Biodegradable delivery systems of biologically active substances |
| RU2271196C2 (ru) * | 1999-06-04 | 2006-03-10 | Элзэ Копэрейшн | Имплантируемая композиция (варианты) и способ ее приготовления |
| JP2004511431A (ja) * | 2000-06-28 | 2004-04-15 | アトゥル・ジェイ・シュクラ | 生物活性物質を含む生分解性ビヒクルおよび送達システム |
| WO2002038185A2 (en) * | 2000-11-13 | 2002-05-16 | Atrix Laboratories, Inc. | Injectable sustained release delivery system with loperamide |
| WO2002058670A1 (en) | 2001-01-25 | 2002-08-01 | Euroceltique S.A. | Local anesthetic, and method of use |
| ATE427760T1 (de) * | 2001-02-23 | 2009-04-15 | Genentech Inc | Erodierbare polymere zur injektion |
| CA2466632C (en) * | 2001-11-14 | 2014-02-11 | Alza Corporation | Injectable depot compositions and uses thereof |
| MXPA04004664A (es) * | 2001-11-14 | 2004-09-10 | Alza Corp | Composiciones de deposito inyectables. |
| MXPA04004665A (es) * | 2001-11-14 | 2004-09-10 | Alza Corp | Composiciones de deposito inyectable y uso de los mismos. |
| US20040001889A1 (en) * | 2002-06-25 | 2004-01-01 | Guohua Chen | Short duration depot formulations |
| TWI353854B (en) | 2002-06-25 | 2011-12-11 | Alza Corp | Short duration depot formulations |
| BR0313539A (pt) * | 2002-07-31 | 2005-06-21 | Alza Corp | Composições depósito de polìmero multimodais injetáveis e seus usos |
| WO2004012703A1 (en) * | 2002-07-31 | 2004-02-12 | Alza Corporation | Injectable depot compositions and uses thereof |
| US20050281879A1 (en) * | 2003-11-14 | 2005-12-22 | Guohua Chen | Excipients in drug delivery vehicles |
| US20050106214A1 (en) * | 2003-11-14 | 2005-05-19 | Guohua Chen | Excipients in drug delivery vehicles |
-
2003
- 2003-11-04 RU RU2005117164/15A patent/RU2355385C2/ru active
- 2003-11-04 NZ NZ539810A patent/NZ539810A/en unknown
- 2003-11-04 KR KR1020057008166A patent/KR20050088288A/ko not_active Ceased
- 2003-11-04 EP EP03786595A patent/EP1581181B1/en not_active Expired - Lifetime
- 2003-11-04 PL PL377333A patent/PL377333A1/pl not_active Application Discontinuation
- 2003-11-04 JP JP2004551819A patent/JP2006508127A/ja active Pending
- 2003-11-04 CN CNA2003801039719A patent/CN1713890A/zh active Pending
- 2003-11-04 MX MXPA05004927A patent/MXPA05004927A/es unknown
- 2003-11-04 CA CA2504608A patent/CA2504608C/en not_active Expired - Fee Related
- 2003-11-04 BR BR0315304-5A patent/BR0315304A/pt not_active IP Right Cessation
- 2003-11-04 DE DE60325511T patent/DE60325511D1/de not_active Expired - Lifetime
- 2003-11-04 AU AU2003295409A patent/AU2003295409B2/en not_active Ceased
- 2003-11-04 WO PCT/US2003/035416 patent/WO2004043432A2/en not_active Ceased
- 2003-11-04 US US10/701,939 patent/US7368126B2/en not_active Expired - Fee Related
- 2003-11-04 AT AT03786595T patent/ATE418323T1/de not_active IP Right Cessation
- 2003-11-05 MY MYPI20034232A patent/MY140155A/en unknown
- 2003-11-06 UY UY28067A patent/UY28067A1/es not_active Application Discontinuation
- 2003-11-06 TW TW092131019A patent/TW200503774A/zh unknown
- 2003-11-06 AR ARP030104083A patent/AR041913A1/es not_active Application Discontinuation
- 2003-11-06 PE PE2003001127A patent/PE20040675A1/es not_active Application Discontinuation
- 2003-11-06 CL CL200302277A patent/CL2003002277A1/es unknown
-
2005
- 2005-05-05 MA MA28260A patent/MA27523A1/fr unknown
- 2005-06-01 NO NO20052635A patent/NO20052635L/no not_active Application Discontinuation
- 2005-06-02 ZA ZA200504529A patent/ZA200504529B/en unknown
- 2005-06-06 EC EC2005005838A patent/ECSP055838A/es unknown
- 2005-12-22 EC EC2005006249A patent/ECSP056249A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006508127A5 (ja) | ||
| RU2005117164A (ru) | Композиции пролонгированного действия с контролируемым высвобождением | |
| WO2005009408B1 (en) | Sustained release dosage forms of anesthetics for pain management | |
| JP2021035605A (ja) | 活性剤の送達のための微細構造アレイ | |
| JP2005514349A5 (ja) | ||
| CN103491946B (zh) | 可生物降解的药物释放组合物 | |
| CA2275525A1 (en) | Gel composition and methods | |
| HK1220628A1 (zh) | 包含高粘度液体载体的可注射控制释放组合物 | |
| JP2009510116A5 (ja) | ||
| JP2002226399A5 (ja) | ||
| JP2015522001A5 (ja) | ||
| JP2007211030A (ja) | 粘膜表面および身体組織に付与可能な薬学的ゲル調製物 | |
| HRP20250339T1 (hr) | Farmaceutski pripravak | |
| AR103981A1 (es) | Métodos y composiciones particularmente para el tratamiento del trastorno por déficit de atención | |
| HRP20201991T1 (hr) | Sustav za isporuku tekućeg polimera za produženu administraciju lijekova | |
| CA2900920C (en) | Microneedle coating composition and microneedle device | |
| HRP20161138T1 (hr) | Farmaceutski pripravak za oralnu primjenu | |
| JPWO2022004859A5 (ja) | ||
| JP2005533081A5 (ja) | ||
| AU2019203214B2 (en) | Sustained release of bimatoprost, bimatoprost analogs, prostamides and prostaglandins for fat reduction | |
| JP2013530931A5 (ja) | ||
| JP2016520561A5 (ja) | ||
| JP2009249348A (ja) | 塩酸ブテナフィン含有水性貼付剤 | |
| JP2008522972A5 (ja) | ||
| EP3986491B1 (en) | Crosslinkable hydrogel compositions |